Health Prob Civil.
1. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312): 1700-1712. https://doi.org/10.1016/S0140-6736(21)02143-7
2.
Tylš F, Páleníček T, Horáček J. Psilocybin-summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014; 24(3): 342-56. https://doi.org/10.1016/j.euroneuro.2013.12.006
3.
Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022; 14(10): e30214. https://doi.org/10.7759/cureus.30214
4.
Smausz R, Neill J, Gigg J. Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology. J Psychopharmacol. 2022; 36(7): 781-793. https://doi.org/10.1177/02698811221092508
5.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. Molecules. 2021; 26(10): 2948. https://doi.org/10.3390/molecules26102948
6.
Yu Z, Burback L, Winkler O, Xu L, Dennett L, Vermetten E, et al. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. Front Psychiatry. 2024; 15: 1386321. https://doi.org/10.3389/fpsyt.2024.1386321
7.
Reed F, Foldi CJ. Do the therapeutic effects of psilocybin involve actions in the gut?. Trends Pharmacol Sci. 2024; 45(2): 107-117. https://doi.org/10.1016/j.tips.2023.12.007
8.
Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open. 2024; 7(4): e245960. https://doi.org/10.1001/jamanetworkopen.2024.5960
9.
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022; 36(2): 151-158. https://doi.org/10.1177/02698811211073759
10.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021; 384(15): 1402-1411. https://doi.org/10.1056/NEJMoa2032994
11.
Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024; 385: e078084. https://doi.org/10.1136/bmj-2023-078084
12.
Dawood Hristova JJ, Pérez-Jover V. Psychotherapy with psilocybin for depression: systematic review. Behav Sci (Basel). 2023; 13(4): 297.. https://doi.org/10.3390/bs13040297
13.
Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023; 330(9): 843-853. https://doi.org/10.1001/jama.2024.0828
14.
Olivier B, Olivier JDA. Efficacy, Safety, and tolerability of psychedelics in treatment-resistant depression (TRD). Adv Exp Med Biol. 2024; 1456: 49-66. https://doi.org/10.1007/978-981-97-4402-2_3
15.
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022; 56: 101809. https://doi.org/10.1016/j.eclinm.2023.101841
16.
Lyons A. Self-administration of psilocybin in the setting of treatment-resistant depression. Innov Clin Neurosci. 2022; 19(7-9): 44-47.
17.
Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. Esketamine and psilocybin – the comparison of two mind-altering agents in depression treatment: systematic review. Int J Mol Sci. 2022; 23(19): 11450. https://doi.org/10.3390/ijms231911450
18.
Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, et al. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep. 2024; 14(1): 2929. https://doi.org/10.1038/s41598-024-53188-9
19.
Harari R, Chatterjee I, Getselter D, Elliott E. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. iScience. 2024; 27(5): 109686. https://doi.org/10.1016/j.isci.2024.109686
20.
King F, Hammond R. Psychedelics as reemerging treatments for anxiety disorders: possibilities and challenges in a nascent field. Focus (Am Psychiatr Publ). 2021; 19(2): 190-196. https://doi.org/10.1176/appi.focus.20200047
21.
Feulner L, Sermchaiwong T, Rodland N, Galarneau D. Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner J. 2023; 23(4): 315-328. https://doi.org/10.31486/toj.23.0076
22.
Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investig. 2021; 18(10): 958-967. https://doi.org/10.30773/pi.2021.0209
23.
Naulls S, Bunn S. Psychedelic-assisted therapy to treat anxiety disorders [Internet]. UK Parliament; 2024 Feb 5 [cited 2024 Sep 15]. Available from: https://doi.org/10.58248/RR10
24.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016; 30(12): 1181-1197. https://doi.org/10.1177/0269881116675513
25.
Bogadi M, Kaštelan S. A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. Croat Med J. 2021; 62(5): 528-530. https://doi.org/10.3325/cmj.2021.62.528
26.
McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022; 21(6): 463-73. https://doi.org/10.1038/s41573-022-00421-7
27.
van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023; 14: 1134454. https://doi.org/10.3389/fpsyt.2023.1134454
28.
Jones G, Lipson J, Nock MK. Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Sci Rep. 2022; 12: 10578. https://doi.org/10.1038/s41598-022-14809-3
29.
Spoelstra SK, Schoevers RA, Venema SD, Knegtering H. Psychedelics as a potential treatment for tobacco use disorder: a systematic review. Discov Ment Health. 2024; 4: 37. https://doi.org/10.1007/s44192-024-00095-0
30.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015; 29(3): 289-99. https://doi.org/10.1177/0269881114565144
31.
Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022; 79(10): 953-962. https://doi.org/10.1001/jamapsychiatry.2022.2982
32.
Benvenuti F, Colombo D, Soverchia L, Cannella N, Domi E, Ciccocioppo R. Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories. Psychopharmacology (Berl). 2023; 240(7): 1521-1530. https://doi.org/10.1007/s00213-023-06384-w
33.
Biscoe N, Bonson A, Slavin M, Busuttil W, MacManus D, Cox A, et al. Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: a feasibility study protocol. Eur J Trauma Dissoc. 2023; 7(4): 100359. https://doi.org/10.1016/j.ejtd.2023.100359
34.
Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V. Trauma-informed care in psychedelic therapy research: a qualitative literature review of evidence-based psychotherapy interventions in PTSD and psychedelic therapy across conditions. Neuropsychiatr Dis Treat. 2024; 20: 109-135. https://doi.org/10.2147/NDT.S432537
35.
Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022; 439: 120302. https://doi.org/10.1016/j.jns.2022.120302
36.
Woodburn SC, Levitt CM, Koester AM, Kwan AC. Psilocybin facilitates fear extinction: importance of dose, context, and serotonin receptors. ACS Chem Neurosci. 2024;1 5(16): 3034-3043. https://doi.org/10.1021/acschemneuro.4c00279
37.
Averill LA, Abdallah CG. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs. 2022; 31(2): 133-137. https://doi.org/10.1080/13543784.2022.2035358
38.
Du Y, Li Y, Zhao X, Yao Y, Wang B, Zhang L, et al. Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. Chin Med J (Engl). 2023; 136(24): 2983-2992. https://doi.org/10.1097/CM9.0000000000002647
39.
Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020; 27: 100538. https://doi.org/10.1016/j.eclinm.2020.100538
40.
Norred MA, Zuschlag ZD, Hamner MB. A neuroanatomic and pathophysiologic framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder. Drugs. 2024; 84(2): 149-164. https://doi.org/10.1007/s40265-023-01983-5
41.
Attia E, Steinglass JE. Psilocybin for anorexia nervosa: if it helps, let's learn how. Med. 2023; 4(9): 581-2. https://doi.org/10.1016/j.medj.2023.08.003
42.
Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023; 29(8): 1947-1953. https://doi.org/10.1038/s41591-023-02455-9
43.
Majić T, Ehrlich S. Psilocybin for the treatment of anorexia nervosa. Nat Med. 2023; 29(8): 1906-1907. https://doi.org/10.1038/s41591-023-02458-6
44.
Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, et al. Use of selective alternative therapies for treatment of OCD. Neuropsychiatr Dis Treat. 2023; 19: 721-732. https://doi.org/10.2147/NDT.S403997
45.
Owe-Larsson M, Kamińska K, Buchalska B, Mirowska-Guzel D, Cudnoch-Jędrzejewska A. Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacol Rep. 2024;76(5):911-925. doi:10.1007/s43440-024-00633
46.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006; 67(11): 1735-40. https://doi.org/10.4088/JCP.v67n1110
47.
Roscoe J, Lozy O. Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Sci Policy Law. 2022; 8. https://doi.org/10.1177/20503245221085222
48.
Frecska E. Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens. In: Roberts T, Winkelman M, editors. Psychedelic medicine. Westport, CT: Praeger; 2007. p. 69-95.
49.
Zeifman RJ, Kettner H, Pagni BA, Mallard A, Roberts DE, Erritzoe D, et al. Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Sci Rep. 2023; 13(1): 13645. https://doi.org/10.1038/s41598-023-40856-5
50.
Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022; 36(8): 965-973. https://doi.org/10.1177/02698811221084063
51.
Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12): 1268-1278. https://doi.org/10.1177/0269881116662634
52.
Franz M, Regele H, Kirchmair M, Kletzmayr J, Sunder-Plassmann G, Hörl WH, et al. Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure. Nephrol Dial Transplant. 1996; 11(11): 2324-27. https://doi.org/10.1093/oxfordjournals.ndt.a027160
53.
van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011; 59(3): 423-9. https://doi.org/10.1016/j.yrtph.2011.01.006
54.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018; 142: 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012
55.
Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, et al. Psychedelics and sexual functioning: a mixed-methods study. Sci Rep. 2024;1 4(2181). https://doi.org/10.1038/s41598-023-49817-4
56.
Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, et al. The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol. 2022; 36(1): 114-125. https://doi.org/10.1177/02698811211064720
Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.